Biophytis announces its participation in several events in Europe and the United States over the coming months

Biophytis outcomes for patients suffering from age-related diseases, has announced its participation in several conferences until the end of the first half of 2024.

Annual scientific conference on sarcopenia

Biophytis management will take part in the 14th International Conference on Frailty and Sarcopenia Research, which brings together doctors and researchers specializing in sarcopenia and will be held in Albuquerque from 20 to 22 March 2024.

The International Conference on Frailty & Sarcopenia Research is the major international scientific event on sarcopenia, bringing together leading researchers and doctors as well as pharmaceutical and biotechnology companies.

Several business development conferences to find partners

Biophytis will be participating in the coming months in:

  • The BIO-Europe Spring from March 18 to 20, 2024 in Barcelona,
  • The Pharma Partnering Summit on May 22 and 23, in Basel,
  • The BIO International Convention in San Diego from June 3 to 6.

These various events will provide Biophytis with an opportunity to present the company’s latest advances, meet investors from both the US and Europe, and establish links with partners in the pharmaceutical industry with a view to potential research or marketing partnerships.

BIO-Europe Spring is the first event early-year event dedicated to partnerships in the life sciences, bringing together over 3,700 participants, including over 2,000 companies, and connecting the global biopharmaceutical community through thousands of meetings.

The Pharma Partnering Summit is the annual forum dedicated to the healthcare sector, bringing together biotech and MedTech companies, pharmaceutical industries, and institutional investors on a one-to-one basis.

The BIO International Convention is one of the most eagerly awaited events in the biotech sector, attracting more than 20,000 business leaders. It gives industry leaders the opportunity to meet plenty of investors and to get closer to the major companies in the pharmaceutical sector.